TNFRSF8 and non-Hodgkin lymphoma: A phase 2 single-arm trial evaluated BV monotherapy in r/r NHL patients with high CD30 expression; in the 7 NKTCL patients, CR and partial remission (PR) was reported in 1 patient each [22].